Van Coillie, Samya
Van San, Emily
Goetschalckx, Ines
Wiernicki, Bartosz http://orcid.org/0000-0003-2694-8986
Mukhopadhyay, Banibrata
Tonnus, Wulf http://orcid.org/0000-0002-9728-1413
Choi, Sze Men
Roelandt, Ria
Dumitrascu, Catalina
Lamberts, Ludwig
Dams, Geert
Weyts, Wannes
Huysentruyt, Jelle
Hassannia, Behrouz
Ingold, Irina
Lele, Suhas
Meyer, Evelyne
Berg, Maya
Seurinck, Ruth http://orcid.org/0000-0002-6636-7572
Saeys, Yvan
Vermeulen, An
van Nuijs, Alexander L. N.
Conrad, Marcus http://orcid.org/0000-0003-1140-5612
Linkermann, Andreas http://orcid.org/0000-0001-6287-9725
Rajapurkar, Mohan
Vandenabeele, Peter http://orcid.org/0000-0002-6669-8822
Hoste, Eric
Augustyns, Koen http://orcid.org/0000-0002-5203-4339
Vanden Berghe, Tom http://orcid.org/0000-0002-1633-0974
Article History
Received: 15 April 2021
Accepted: 7 February 2022
First Online: 24 February 2022
Competing interests
: T.V.B., P.V., and K.A. hold patents US9862678, WO2016075330, EP3218357, and WO2019154795 related to ferrostatin-1 analogs. M.R. and S.L. report holding United States patents (US 7,927,880 B2 19 April 2011 and US 8,192,997 B2 5 June 2012) and European patents (EP2250500B, 24 April 2013) for the methods and kit for the measurement of serum catalytic iron for early detection of acute coronary syndrome and prediction of adverse cardiac events. A.L. issued a patent for Nec-1f, an inhibitor of ferroptosis (20160943.5). M.C. is co-founder and shareholder of ROSCUE Therapeutics GmbH. The remaining authors declare no competing interests.